4100 Group led an extension to the Stanford-StartX Fund-backed healthcare AI technology provider's latest round, which now stands at $30m.
Gauss, a US-based healthcare computer vision technology developer, has added $10m to a series C round already backed by the Stanford University-aligned Stanford-StartX Fund to bring the total to $30m.
Dental care provider Delta Dental of Michigan and Ohio led the extension through its subsidiary 4100 Group and was joined by SoftBank Ventures Asia – part of telecoms group SoftBank – as well as health systems Northwell Health, OSF Healthcare and Providence Health and Services, in addition to venture capital firm Polaris Partners.
Gauss has created a computer vision system that identifies surgical and obstetric haemorrhages in real time and alerts clinicians.
The series C proceeds will support clinical testing of an at-home diagnostics test for covid-19 the company is developing with point-of-care diagnostic test provider Cellex. Scott Lancaster, managing director of private market investments for 4100 Group, is joining its board of directors.
All the participants in the extension also contributed to the round’s $20m first tranche in late 2018, with OSF, Providence and Polaris taking part through subsidiaries OSF Ventures, Providence Ventures and LS Polaris Innovation Fund.
The first close also featured care providers Memorial Hermann Health System, UNC/Rex Healthcare, Orlando Health, Spectrum Health and Mount Sinai Health System, the last four through Rex Health Ventures, Orlando Health Ventures, Spectrum Health Ventures and Mount Sinai Ventures.
Gauss has now raised $54.6m since it was founded in 2011, including $12.6m in series B funding from investors including Stanford-StartX Fund and Summation Health Ventures, which was formed by healthcare providers Cedars-Sinai Health System and MemorialCare Health System, in 2016.
Promus Ventures, LifeForce Ventures and Jump Capital filled out the series B round, which was preceded by a $12m series A led by Promus Ventures and backed by Summation Health Ventures and LifeForce Ventures the year before. Its earlier investors include Taube Investment Partners.
– A version of this article first appeared on our sister site, Global Corporate Venturing.